Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

Not Applicable

Completed

• Conditions: Brain Cancer

• Registration Number: NCT02849171
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

This is a pilot study. The purpose of this study is to test if an imaging tracer, not approved by the FDA, called 11C-Choline (11C-CH) is useful for evaluating your type of cancer. This tracer is used to perform PET scans. The researchers want to see if the 11C-CH PET scan, using the study tracer 11C-CH, can improve upon the usual scans at diagnosing or monitoring your type of cancer.

In patients with high-grade gliomas, changes on standard MRI of the brain may reflect true tumor growth or inflammatory changes in response to treatment, called pseudo-progression. It is important to distinguish true tumor growth from inflammation since inflammation indicates the tumor is responding to treatment. With standard MRI, it is difficult to determine if changes following treatment are due to tumor growth or inflammation early on. Researchers hope to learn if the investigational tracer, 11C-CH, will be able to distinguish true tumor growth from inflammation more accurately than standard MRI or 18F-FDG PET scans.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-07
• Study First Submitted: 2016-07-12
• Study First Submitted QC: 2016-07-28
• Study First Posted: 2016-07-29
• Status Verified: 2022-05
• Primary Completion: 2022-05-06
• Study Completion: 2022-05-06
• Results First Submitted: 2022-09-06
• Results First Submitted QC: 2022-12-01
• Last Update Submitted: 2022-12-01
• Results First Posted: 2022-12-29
• Last Update Posted: 2022-12-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Age ≥ 18 years
• Patient is able to provide written informed consent prior to study registration
• Histologically-confirmed high-grade glioma
• Completion of treatment with standard radiation (with or without concurrent therapy).
• Standard gadolinium-enhanced MRI changes that are considered indeterminate for tumor progression vs. treatment-related changes by the neuroradiologist or clinician within 24 weeks of completion of radiation.

Exclusion Criteria

• Inability to undergo or cooperate with an MRI or PET scan (e.g., claustrophobia, metal implant)
• Renal insufficiency with recent (<3 month old) creatinine > 2.0 mg/dL
• Pregnant or nursing female

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
SUV Measures	1 year	from 11C-CH PET with evolving changes on brain MRI in high-grade glioma after radiotherapy. In a small subgroup of patients required surgery, tissue will be analyzed for histopathologic correlate. The data gathered will not be considered definitive, but rather will be used to as preliminary data in support of a larger, definitive study.

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States